مباشر
FierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from expertsLonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma LetterLabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech mediaLonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma PostEli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSNThermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo FinanceeLifeThe NTR/prodrug revolution: Tools for controlling cell loss and regenerationBio-Gene Technology LtdBio-Gene lifts placement size with additional shares and options - TipRanks10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.comEli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - StocktwitsPfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord PharmaEndpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for Voyxact
PharmaVoice ٩ مارس ٢٠٢٦

The first KRAS drugs have been sluggish on the market. Will the next generation fare better?

The first KRAS drugs have been sluggish on the market. Will the next generation fare better?

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.